May 28 |
Sight Sciences Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNIĀ® Across Mild, Moderate, and Advanced Glaucoma
|
May 7 |
Sight Sciences to Present at the Upcoming Bank of America Healthcare Conference
|
May 6 |
Sight Sciences, Inc. (NASDAQ:SGHT) Q1 2024 Earnings Call Transcript
|
May 5 |
Sight Sciences, Inc. (SGHT) Q1 2024 Earnings Call Transcript
|
May 4 |
Sight Sciences First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
May 3 |
Q1 2024 Sight Sciences Inc Earnings Call
|
May 3 |
Sight Sciences GAAP EPS of $0.33, revenue of $19.3M
|
May 2 |
Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Tops Revenue Estimates
|
May 2 |
Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance
|
Apr 29 |
Sector Update: Health Care Stocks Edge Higher Late Afternoon
|